Cilostazol-d2

Cilostazol-d2 (OPC 13013-d2) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

Product Specifications

CAS Number

1073608-03-3

Product Name Alternative

OPC 13013-d2

UNSPSC

12352005

Target

Autophagy; Isotope-Labeled Compounds; Phosphodiesterase (PDE)

Related Pathways

Autophagy; Metabolic Enzyme/Protease; Others

Applications

Cancer-programmed cell death

Field of Research

Cardiovascular Disease; Cancer

Smiles

O=C1NC2=CC=C(C=C2CC1)OCCCCC3=NN=NN3C4CCC([2H])([2H])CC4

Molecular Formula

C20H25D2N5O2

Molecular Weight

371.47

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Schr?r K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002 Mar;4 Suppl 2:S14-9.|[3]Ye YL, et al. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.Eur J Pharmacol. 2007 Feb 14;557 (1) :23-31. Epub 2006 Nov 10.|[4]Minami N, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997;61 (25) :PL 383-9.|[5]Saito S, et al. Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis. Hepatol Res. 2013 Apr 19.